Abeona Therapeutics (NASDAQ:ABEO) Downgraded by StockNews.com to Sell

StockNews.com downgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a sell rating in a research report released on Saturday morning.

ABEO has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Trading Down 0.7 %

Shares of Abeona Therapeutics stock opened at $5.78 on Friday. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The stock has a market cap of $251.26 million, a P/E ratio of -2.15 and a beta of 1.43. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $5.65 and its 200-day moving average is $5.82.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Twinbeech Capital LP bought a new stake in Abeona Therapeutics in the 4th quarter valued at $58,000. Northern Trust Corp raised its stake in Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 11,478 shares during the period. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics in the 4th quarter valued at $67,000. Jane Street Group LLC bought a new stake in Abeona Therapeutics in the 3rd quarter valued at $84,000. Finally, Oxford Asset Management LLP acquired a new position in Abeona Therapeutics in the 4th quarter valued at $118,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.